



GROMMET INSERTION RECURRENT ACUTE OTITIS MEDIA (WITHOUT EFFUSION) CRITERIA BASED ACCESS (CBA) POLICY

Version:	2425.v3
Recommendation by:	NHS Somerset ICB Clinical Commissioning Policy Forum (CCPF)
Date Ratified:	January 2025
Name of Originator/Author:	EBI Service
Approved by Responsible Committee/Individual:	NHS Somerset Management Board
Publication/issue date:	April 2025
Review date:	Earliest of either NICE publication or 3 years from issue
Target audience:	 NHS Somerset ICB: NHS Providers GP Practices Contracts Team Medical Directors: Somerset NHS Foundation Trust Royal United Hospitals Bath NHS FT
Application Form	EBI Generic application form if appropriate to apply

GROMMET INSERTION RECURRENT ACUTE OTITIS MEDIA (WITHOUT EFFUSION) CRITERIA BASED ACCESS (CBA) POLICY

Section	CONTENTS	Page
	Version Control	1
1	General Principles	2
2	Policy Criteria	2-3
3	Background	3-4
4	Evidence Based Interventions Application Process	4-5
5	Access To Policy	5
6	References	5

VERSION CONTROL

Document Status:	Current policy
Version:	2425.v3

DOCUMENT CHANGE HISTORY			
Version	Date	Comments	
1718.v1	March 2020	New policy template & PALs email address Rebranding from IFR to EBI	
1920.v3	September 2020	Update General Principles & EBIP process, 3- year review CCPF no amendments	
2021.v2	July 2022	Amendment from SCCG to NHS Somerset ICB. New PALS email address	
2223.v2a	January 2024	3-year review, no clinical amendments. Amendment to website link on 4.6	
2324.v4b	January 2025	Change from CBA to PA pathway from 01 April 2025	

Equality Impact Assessment (EIA)	N/A
Quality Impact Assessment QIA	March 2018
Sponsoring Director:	Dr Bernie Marden
Document Reference:	2425.v3

1 GENERAL PRINCIPLES (CBA)

- 1.1 Treatment should only be given in line with these general principles.
- 1.2 Clinicians should assess their patients against the criteria within this policy AND ENSURE that compliance to the policy criteria is met by the patient PRIOR TO a referral to treatment or surgery
- 1.3 Treatment should ONLY be undertaken where there is evidence that the treatment requested is effective and the patient has the potential to benefit from the proposed treatment
- 1.4 The ICB may approve funding for an ASSESSMENT ONLY to enable the Clinician to obtain further clinical evidence to help determine compliance to policy criteria by the patient.

In such cases, patients should be made aware that an assessment DOES NOT mean that they will automatically receive the treatment or surgery. The patient should be advised that, to effectively manage patient safety and ensure efficacy of the treatment/ surgery for the patient, they will only receive treatment or surgery if they meet policy criteria

- 1.5 Patients MUST CONSENT to receiving treatment/ surgery prior to treatment being undertaken
- 1.6 This policy does not apply to patients with suspected malignancy who should continue to be referred under the NHS '2 week wait pathway' rules for assessment and testing as appropriate
- 1.7 Patients with an elevated BMI of 30 or more MAY experience more postsurgical complications including post-surgical wound infection and should be encouraged to lose weight further prior to seeking surgery

https://www.sciencedirect.com/science/article/pii/S1198743X15007193 (Thelwall, 2015)

- 1.8 Patients who are smokers should be referred to smoking cessation services to reduce the risk of surgery and improve healing
- 1.9 Where patients are unable to meet the specific treatment criteria set out in this policy, funding approval MAY be sought by submission of a Generic EBI application form to the Evidence Based Interventions (EBI) team on grounds of 'clinical exceptionality'

2 POLICY CRITERIA – CRITERIA BASED ACCESS (CBA)

Emergency admission for rare serious complications of AOM are not restricted by this policy

The Commissioner will agree to fund a surgical referral for a patient with recurrent acute otitis media (without effusion) to include consideration of insertion of grommets, where the following criteria have been met:

- 2.1 The patient has had at least 5 separate recurrences of acute otitis media (with or without treatment) in the previous 12 months, documented in their primary care records (AOM does not routinely require antibiotics) **OR**
- 2.2 The patient has an episode of Acute Otitis Media (AOM) associated with any of the following:
 - a. Intracranial infection
 - b. Acute mastoiditis
 - c. Facial paralysis
 - d. Neck abscess
- 2.4 Patients who are not eligible for treatment under this policy, please refer to section 4 EVIDENCE BASED INTERVENTIONS APPLICATION PROCESS on how to apply for funding with evidence of clinical exceptionality

3 BACKGROUND

3.1 Guidance on referrals for advice and guidance only

GPs requests for specialist advice on ear problems where AOM may be a factor, fall outside this policy statement, however funding approval will need to be secured from the Commissioner prior to any subsequent surgery

3.2 Diagnosis by ENT and/or Audiology

It is important to obtain a diagnosis for recurrent otorrhoea, in particular to exclude cholesteatoma, which is often referred to secondary care in an advanced stage. Where the GP is unable to obtain a good view of the entire tympanic membrane and confidently state that it is normal in between episodes of otorrhoea, an ENT opinion should be sought. If there is any concern about hearing loss in between these episodes, a referral should be made for audiometry

3.3 Antibiotics

The majority of cases of AOM will resolve spontaneously. Without specific treatment symptoms improve within 24 hours in 60% of children and settle within three days in 80% of children. Whilst adequate analgesia should be prescribed in all cases, antibiotics should be avoided in mild-to-moderate cases and when there is diagnostic uncertainty in patients aged 2 years

and under. The Somerset ICB infection management guidance should be consulted. <u>http://formulary.somerseticb.nhs.uk/?page_id=203</u>

- 3.4 A Cochrane Collaboration systematic review has concluded:
- 3.4.1 Acute otitis media is a common disease of childhood, involving inflammation of the space behind the eardrum (the middle ear cleft). Episodes typically involve a fever and a build-up of pus that stretches the eardrum causing severe pain. The drum may then rupture, relieving the pain, and a discharge of pus enters the ear canal. A small proportion of children suffer with recurrent acute otitis media, which is defined as either three or more acute infections of the middle ear cleft in a six-month period, or at least four episodes in a year
- 3.4.2 One of the strategies used to treat this condition is the insertion of a miniature plastic ventilation tube (or grommet) into the eardrum, which prevents the painful accumulation of pus in the middle ear. This review aims to assess the evidence for the effectiveness of this treatment in reducing recurrent acute otitis media
- 3.4.3 We searched for scientific studies which compared treating children with recurrent acute otitis media with either grommets or a non-surgical treatment such as antibiotics (or no treatment). In these studies, children with grommets in place were considered to have suffered an episode of acute otitis media if they had a discharge of pus from the ear
- 3.4.4 Two suitable studies were found to be suitable for further analysis. The combined results from these two studies suggested that more children treated with grommets are rendered symptom-free in the six months following surgery compared to those who receive other treatments or no treatment. One of the two included studies, involving 95 children, showed that grommets reduce the number of episodes of acute otitis media in the first six months after surgery, by an average of 1.5 episodes per child
- 3.4.5 When considering the size of this effect, it is important to bear in mind that the studies were not perfect in their design and execution. To be confident in these findings further high-quality research is required.'

4 EVIDENCE BASED INTERVENTIONS APPLICATION PROCESS

4.1 Patients who are not eligible for surgery under this policy may be considered for surgery on an individual basis where the 'CLINICIAN BEST PLACED' believes exceptional circumstances exist that warrant deviation from the rule of this policy

'THE CLINICIAN BEST PLACED' is deemed to be the GP or Consultant undertaking a medical assessment and/or a diagnostic test/s to determine the health condition of the patient 4.2 Completion of a **Generic EBI Funding Application Form** must be sent to the EBI team by the 'clinician best placed' on behalf of the patient

Note. applications CANNOT be considered from patients personally

- 4.3 Only electronically completed EBI applications emailed to the EBI Team will be accepted
- 4.4 It is expected that clinicians will have ensured that the patient, on behalf of whom they are forwarding the funding application, has given their consent to the application and are made aware of the due process for receiving a decision on the application within the stated timescale
- 4.5 Generic EBI Funding Applications are considered against 'clinical exceptionality'. To eliminate discrimination for patients, social, environmental, workplace, and non-clinical personal factors CANNOT be taken into consideration.

For further information on 'clinical exceptionality' please refer to the NHS Somerset ICB EBI webpage <u>Evidence Based Interventions - NHS Somerset</u> ICB and click on the section titled **Generic EBI Pathway**

4.6 Where appropriate photographic supporting evidence can be forwarded with the application form

5 ACCESS TO POLICY

- 5.1 If you would like further copies of this policy or need it in another format, such as Braille or another language, please contact the Patient Advice and Liaison Service on Telephone number: 08000 851067
- 5.2 **Or write to us**: NHS Somerset ICB, Freepost RRKL-XKSC-ACSG, Yeovil, Somerset, BA22 8HR or **Email** us: <u>somicb.pals@nhs.net</u>

6 **REFERENCES**

The following sources have been considered when drafting this policy:

6.1 McDonald S, Langton Hewer CD, Nunez DA. Grommets (ventilation tubes) for recurrent acute otitis media in children. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD004741. DOI: 10.1002/14651858.CD004741.pub2